Literature DB >> 22508525

Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation.

Hugo Kaneku1, Jacqueline G O'Leary, Michiko Taniguchi, Brian M Susskind, Paul I Terasaki, Göran B Klintmalm.   

Abstract

In a previous study, we found that 92% of patients with chronic rejection had donor-specific human leukocyte antigen antibodies (DSAs), but surprisingly, 61% of comparator patients without rejection also had DSAs. We hypothesized that immunoglobulin G (IgG) subclasses were differentially distributed between the 2 groups. A modified single-antigen bead assay was used to detect the presence of individual IgG subclasses against human leukocyte antigen in 39 chronic rejection patients and 66 comparator patients. DSAs of the IgG1 subclass were most common and were found in 45% of all patients; they were followed by IgG3 DSAs (21%), IgG4 DSAs (14%), and IgG2 DSAs (13%). The percentage of patients with multiple IgG subclasses was significantly higher in the chronic rejection group versus the comparator group (50% versus 14%, P < 0.001). Patients with normal graft function in the presence of DSAs mostly had isolated IgG1, whereas patients with chronic rejection had a combination of IgG subclasses. Patients who developed DSAs of the IgG3 subclass showed an increased risk of graft loss (hazard ratio = 3.35, 95% confidence interval = 1.39-8.05) in comparison with patients with DSAs of other IgG subclasses or without DSAs. Although further study is needed, the determination of the IgG subclass in DSA-positive patients may help us to identify patients with a higher risk of chronic rejection and graft loss.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508525     DOI: 10.1002/lt.23451

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  33 in total

1.  Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Authors:  N M Valenzuela; K R Trinh; A Mulder; S L Morrison; E F Reed
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

2.  Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

Authors:  J G O'Leary; H M Gebel; R Ruiz; R A Bray; J D Marr; X J Zhou; S M Shiller; B M Susskind; A D Kirk; G B Klintmalm
Journal:  Am J Transplant       Date:  2013-02-22       Impact factor: 8.086

3.  Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.

Authors:  Laura J Wozniak; Michelle J Hickey; Robert S Venick; Jorge H Vargas; Douglas G Farmer; Ronald W Busuttil; Sue V McDiarmid; Elaine F Reed
Journal:  Transplantation       Date:  2015-07       Impact factor: 4.939

4.  IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.

Authors:  Carmen Lefaucheur; Denis Viglietti; Carol Bentlejewski; Jean-Paul Duong van Huyen; Dewi Vernerey; Olivier Aubert; Jérôme Verine; Xavier Jouven; Christophe Legendre; Denis Glotz; Alexandre Loupy; Adriana Zeevi
Journal:  J Am Soc Nephrol       Date:  2015-08-20       Impact factor: 10.121

5.  Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

Authors:  Denis Viglietti; Alexandre Loupy; Dewi Vernerey; Carol Bentlejewski; Clément Gosset; Olivier Aubert; Jean-Paul Duong van Huyen; Xavier Jouven; Christophe Legendre; Denis Glotz; Adriana Zeevi; Carmen Lefaucheur
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

6.  The role of donor-specific HLA alloantibodies in liver transplantation.

Authors:  J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

7.  Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants.

Authors:  Sandy Feng; John C Bucuvalas; Anthony J Demetris; Bryna E Burrell; Katherine M Spain; Sai Kanaparthi; John C Magee; David Ikle; Andrew Lesniak; Juan J Lozano; Estella M Alonso; Robert A Bray; Nancy E Bridges; Edward Doo; Howard M Gebel; Nitika A Gupta; Ryan W Himes; Annette M Jackson; Steven J Lobritto; George V Mazariegos; Vicky L Ng; Elizabeth B Rand; Averell H Sherker; Shikha Sundaram; Yumirle P Turmelle; Alberto Sanchez-Fueyo
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

Review 8.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Methods Mol Biol       Date:  2013

Review 10.  Liver transplantation: Current status and challenges.

Authors:  Caroline C Jadlowiec; Timucin Taner
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.